Literature DB >> 15081258

Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production.

Henrik Gonzalez1, Mohsen Khademi, Magnus Andersson, Fredrik Piehl, Erik Wallström, Kristian Borg, Tomas Olsson.   

Abstract

The postpolio syndrome (PPS) is characterized by progressive disabilities decades after recovery from the acute paralytic disease. There are reports on intrathecal inflammatory reactions in PPS, including increased expression of cytokines by cerebrospinal fluid (CSF) mononuclear cells (CSF-MC). This is potentially of relevance for the clinical condition. We here explored if cytokine expression in the CSF of PPS patients could be modulated by high-dose intravenous immunoglobulins (IvIg). The expression of TNF-alpha, IFN-gamma, IL-10 and IL-4 mRNAs was measured by real-time RT-PCR in CSF and peripheral blood mononuclear cells (PBMC) of 16 PPS patients before, and 6-8 weeks after IvIg treatment, and in 26 patients with noninflammatory other neurological diseases (OND). TNF-alpha, IFN-gamma and IL-10 CSF mRNA levels were elevated in samples from untreated persons with PPS compared to OND. Upon IvIg treatment, IFN-gamma and TNF-alpha mRNA levels were dramatically reduced, while IL-10 remained unchanged. Placebo-controlled studies are now warranted to evaluate if IvIg treatment also has any effects on the clinical manifestations of PPS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081258     DOI: 10.1016/j.jneuroim.2004.01.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  IVIG treatment in post-polio patients: evaluation of responders.

Authors:  Gunilla Ostlund; Lisbet Broman; Lars Werhagen; Kristian Borg
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

3.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 4.  Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

5.  Update on current and emerging treatment options for post-polio syndrome.

Authors:  Elisabeth Farbu
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

6.  Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.

Authors:  Henrik Gonzalez; Mohsen Khademi; Kristian Borg; Tomas Olsson
Journal:  J Neuroinflammation       Date:  2012-07-09       Impact factor: 8.322

Review 7.  Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis.

Authors:  Yao-Hsien Huang; Hung-Chou Chen; Kuang-Wei Huang; Po-Chih Chen; Chaur-Jong Hu; Chin-Piao Tsai; Ka-Wai Tam; Yi-Chun Kuan
Journal:  BMC Neurol       Date:  2015-03-22       Impact factor: 2.474

8.  Normal serum levels of immune complexes in postpolio patients.

Authors:  Eva Melin; Azita Sohrabian; Johan Rönnelid; Kristian Borg
Journal:  Results Immunol       Date:  2014-06-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.